MedDataX Logo

A New Supplement for the "Metabolic Syndrome"

NCT ID: NCT03813914

Last Updated: 2019-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-15

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of a combination of glycirrhizic acid, Cinnamomun Zeylanicum and corosolic acid for the treatment of metabolic syndrome. Participants receive the supplement or a placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Genistein in Women With Metabolic Syndrome

NCT00541710

Metabolic Syndrome
COMPLETED PHASE2/PHASE3

The Effects of Cilnidipine on Metabolic Syndrome Improvement

NCT00325936

Hypertension Metabolic Syndrome X
COMPLETED PHASE4

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379

Depression Insulin Resistance Metabolic Syndrome
COMPLETED PHASE4

Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients

NCT01300637

Obesity Metabolic Syndrome Schizophrenia
UNKNOWN NA

Impact of Hesperetin in Combination With Sucrose on Energy Metabolism

NCT05705596

Blood Glucose Fluctuations Hunger
COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The supplement is composed by of a combination of glycirrhizic acid, Cinnamomun Zeylanicum and corosolic acid. They act in different way reducing insulin resistance, which is the main cause of metabolic syndrome. It was a randomized, controlled study involving 60 women with the metabolic syndrome following the criteria proposed by ATP III in 2015. Main outcomes were the improvement of the parameters that characterizes the metabolic syndrome, such as glucose and insulin levels, triglycerides, HDL-cholesterol and blood pressure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sineos

Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months

Group Type EXPERIMENTAL

Sineos

Intervention Type DIETARY_SUPPLEMENT

glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day

Placebo comparator

placebo 2 pills/day for 3 months

Group Type PLACEBO_COMPARATOR

Sineos

Intervention Type DIETARY_SUPPLEMENT

glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sineos

glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Messina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rosario D'anna

Principal Investigator, Clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sineos-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
NCT05748990 RECRUITING NA
The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction
NCT00895570 COMPLETED NA
Effect of Oral 6-bromotryptophan on Safety, Pharmacokinetics and Efficacy in Metabolic Syndrome Individuals
NCT05971524 UNKNOWN PHASE1/PHASE2
Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
NCT02751307 COMPLETED PHASE4
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577 COMPLETED PHASE4
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
NCT06707012 RECRUITING PHASE4
Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males
NCT00814931 COMPLETED PHASE1
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00936741 COMPLETED PHASE3
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCT03271866 UNKNOWN NA
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749 COMPLETED PHASE4
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
NCT02708394 COMPLETED EARLY_PHASE1
Berberine Treat Metabolic Syndrome in Schizophrenia
NCT03251716 COMPLETED NA
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 COMPLETED PHASE4
Metabolic Disorders and Vertigo
NCT04935970 UNKNOWN
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
NCT04865835 COMPLETED PHASE1
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620 COMPLETED PHASE4
The Impact of the Mediterranean Diet on Anthropometric Indices, Lipid Profiles, Energy Metabolism Signaling Proteins and Inflammatory Cytokines in Psychiatric Patients With Metabolic Syndrome
NCT07164014 COMPLETED NA
To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets
NCT00913419 COMPLETED PHASE1
An Insulin Sensitivity Study in Healthy Subjects
NCT02922426 COMPLETED PHASE1
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00809536 TERMINATED PHASE1
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
NCT02304432 COMPLETED EARLY_PHASE1
The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity
NCT01384279 COMPLETED NA
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT03277690 COMPLETED PHASE3
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
NCT03708549 UNKNOWN PHASE4
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
NCT01160991 COMPLETED NA